LNP formulations produce strong immune responses, data shows
Drug Discovery World
FEBRUARY 15, 2024
etherna’s Vice President, Technology & Innovation, Stefaan De Koker described the paper as a “landmark” for the company and its technology. Hypothetically, any mRNA-based drug using S-Ac7-DOG as the lipid base would therefore have improved efficacy and a better safety profile.
Let's personalize your content